Abstracts

UNITY-2: Daclatasvir/Asunaprevir/Beclabuvir ± RBV for HCV Genotype 1 With Cirrhosis

Background: The presence of cirrhosis in patients with chronic HCV infection can reduce response to HCV therapies; potent and well tolerated oral regimens are needed. The all-oral DCV-TRIO regimen includes daclatasvir (DCV; pangenotypic NS5A inhibitor), asunaprevir (ASV; NS3 protease inhibitor), and beclabuvir (BCV; non-nucleoside NS5B inhibitor) in a fixed-dose combination (FDC). We evaluated this regimen,…

Utility of Hepatitis C Viral-Load Monitoring With Ledipasvir and Sofosbuvir Therapy

Background: Directly acting antivirals (DAA) are replacing interferon-based hepatitis C therapy. On interferon-based treatment, HCV RNA plasma levels were early predictors of treatment response and mainstays for response-guided therapy. However, the clinical utility of HCV RNA levels to guide duration of DAA therapy has not yet been determined. The aim of this study was to…

Viral Kinetic Profiles of HCV Response to Telaprevir-Based Therapy in Patients With Hemophilia

Background: The majority of patients with inherited bleeding disorders who received blood-derived factor concentrates were infected with HCV with repeated exposures to multiple HCV species. It is hypothesized that wide quasispecies representation could affect treatment responses, and that lead-in might mitigate emergent viral breakthrough. The utility of lead-in vs. DAA-based therapy in hemophiliacs was evaluated…

Hematologic Analysis of ABT-450/r/Ombitasvir and Dasabuvir + RBV in TURQUOISE-I

Background: Combination therapy of ribavirin (RBV)+peginterferon (pegIFN) with protease inhibitors for the treatment of HCV is commonly associated with hematologic abnormalities. We sought to analyze immune parameters in patients co-infected with HCV and HIV-1 treated with the 3 direct-acting antiviral (3D) regimen of co-formulated ABT-450 (identified by AbbVie and Enanta)/ritonavir/ombitasvir and dasabuvir given with weight-based…

Effect of HIV Coinfection on Adherence to a 12-Week Regimen of HCV Therapy With Ledipasvir/Sofosbuvir

Background: The treatment of hepatitis C virus (HCV) infection is rapidly evolving to interferon (IFN) and ribavirin (RBV) free treatment with directly acting antiviral agents (DAAs). The impact of DAAs on HCV treatment adherence in HIV/HCV co-infected populations has not been extensively evaluated. We compared adherence rates of the IFN and RBV free DAA regimen…

Investigation of the Role of Macrocyclization in HCV Protease Inhibitor MK-5172

Background: Structure guided drug design has been a powerful tool for the discovery and development of inhibitors to the viral HCV NS3/4A protease. The NS3/4A protease inhibitors (PIs) have benefited from extensive optimizations in the common P4 capping, P3-P1′ peptidomimetic scaffold and various macrocyclization states. However, neither structural nor thermodynamic information have been presented evaluating…

Mental Health Impact of HCV Treatment in HIV/HCV Patients: DAA vs IFN-Based Therapy

Background: Depression is one of the most important complications of IFN-based chronic hepatitis C treatment, affecting one in four patients. Psychiatric side effects of IFN have significant clinical implications, creating a relative contraindication to IFN in those with mental dissorders. Patients with HIV/HCV-coinfection are particularly vulnerable given the prevalence of psychiatric comorbidities and higher adverse…

Characterization of Naturally Occurring Resistance to HCV NS5A Inhibitors

Background: Clinical trials with some NS5A inhibitor-containing regimens have resulted in less favorable responses among individuals with GT1a compared to GT1b HCV. To assess whether quantitative or qualitative differences in naturally occurring resistant variants may explain the discordant response rates, we used deep sequencing and recombinant replicons to determine the prevalence and resistance profiles of…

Hepatitis C Q80K Prevalence in BC, Canada, Determined by a Public Domain Assay

Background: HCV genotype 1a (GT1a) infections harbouring a baseline Q80K polymorphism in the NS3 gene have reduced virologic response to IFN-based HCV treatments containing simeprevir. We aimed to develop, validate, and freely disseminate a NS3 clinical sequencing assay to detect Q80K and other NS3 mutations, and establish their prevalence in British Columbia (BC), Canada. Methods:…